WINTON GROUP Ltd Buys 25,100 Shares of Genmab A/S Sponsored ADR $GMAB

WINTON GROUP Ltd grew its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 158.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 40,900 shares of the company’s stock after buying an additional 25,100 shares during the period. WINTON GROUP Ltd’s holdings in Genmab A/S were worth $1,124,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Orbis Allan Gray Ltd increased its position in Genmab A/S by 30.2% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock worth $444,089,000 after purchasing an additional 3,340,456 shares during the period. Paradigm Biocapital Advisors LP lifted its position in Genmab A/S by 84.4% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company’s stock valued at $216,827,000 after purchasing an additional 3,222,983 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after purchasing an additional 921,700 shares during the last quarter. Finally, First Trust Advisors LP grew its position in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after buying an additional 1,126,069 shares during the period. Institutional investors own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on GMAB. Truist Financial initiated coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price for the company. New Street Research set a $43.00 price target on Genmab A/S in a research report on Wednesday, July 22nd. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. HC Wainwright upped their price objective on Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Finally, Weiss Ratings raised Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $39.50.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $32.47 on Monday. Genmab A/S Sponsored ADR has a one year low of $23.62 and a one year high of $35.43. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The firm has a market cap of $20.25 billion, a P/E ratio of 25.57, a P/E/G ratio of 1.83 and a beta of 0.84. The stock’s 50-day moving average is $31.00 and its 200-day moving average is $28.26.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. Sell-side analysts anticipate that Genmab A/S Sponsored ADR will post 1.17 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.